UPDATE 1-Stereotaxis sees Q4 rev below analysts' view, shrs fall

(Recasts, adds details, share movement)

Jan 15 (Reuters) - Medical device maker Stereotaxis Inc (STXS.O) forecast quarterly revenue below analysts' view, due to delayed launches of its catheter device for the heart in Europe and the United States, sending its shares down around 17 percent.

In a separate release, the company said the U.S. health regulators approved the device known as partnered magnetic irrigated catheter, which is used in treating complex arrhythmias, or irregular heartbeats.

Stereotaxis, which markets cardiology instrument control systems, forecast fourth-quarter revenue of about $10 million. Analysts on average were expecting $16.5 million, according to Reuters Estimates.

For 2007, the company expects total revenue to increase by about 45 percent to about $39 million. Analysts were expecting $45.5 million.

"The delayed availability of the irrigated catheter has resulted in a lack of clinical reference sites using this device," Chief Executive Bevil Hogg said in a statement.

"This situation has slowed the conversion of pipeline to backlog and backlog to revenue and negatively impacted both revenue and orders during the fourth quarter," Hogg added.

The company, however, expects to regain the order and revenue momentum upon attaining full scale availability of the device in the United States.

Shares of the company fell to $9.50 in after-hour trade, after closing at $11.39 on the Nasdaq. (Reporting by Swagata Gupta in Bangalore; Editing by Anil D'Silva) ((swagata.gupta@reuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: swagata.gupta.reuters.com@reuters.net))